Eli Lilly's oral tau drug fails to show efficacy in a phase 2 trial in Alzheimer's disease in another setback for the class ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...